What is CADL's current stock price?

CADL (Candel Therapeutics, Inc.) is currently trading at $7.99 with a market cap of $438.7M.

What sector is Candel Therapeutics, Inc. in?

Candel Therapeutics, Inc. (CADL) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CADL a good stock to buy?

Analysts have a Buy consensus on CADL with a price target of $15.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CADL Candel Therapeutics, Inc.

Healthcare

$7.99+0.76%ClosedMarket Cap: $438.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.61

P/S

0.00

EV/EBITDA

-4.88

DCF Value

$2.20

FCF Yield

-11.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-60.4%

ROA

-27.0%

ROIC

-28.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-8.9M	$—
Q4 null	$0.00	$-29.5M	$—
FY null	$0.00	$-38.2M	$—
Q3 null	$0.00	$-11.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$15.00

Target (Median)

$15.00

Target Range

$15.00 - $15.00

0 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell

CitigroupBuy

2026-03-18

Canaccord GenuityBuy

2026-03-13

Stephens & Co.Overweight

2025-12-08

Freedom BrokerBuy

2025-11-21

CitigroupBuy

2025-11-14

Trading Activity

Insider Trades

View All

PAPA JOSEPH Cdirector

SellThu Apr 02

Manning Paul Bdirector

SellThu Apr 02

Loggia Nicolettadirector

SellThu Apr 02

Manning Paul Bdirector

BuyThu Feb 26

Tyagarajan Seshuofficer: Chief Technology Officer

SellWed Jan 28

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.58

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Peers